Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...
The two IPOs, which follow radiopharma specialist Aktis Oncology's filing last week, have investors and industry watchers ...
Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...
Eikon Therapeutics is planning to become the second biotech to go public in 2026, in another sign that the public markets are ...
Vietnam Investment Review on MSN
Lynk Pharma reports positive phase III results for Zemprocitinib in RA
HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development ...
Plant City, Florida - January 09, 2026 - PRESSADVANTAGE - WhiteSands Alcohol & Drug Rehab Plant City has published ...
Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback